Phosphodiesterase as a New Therapeutic Target for the Treatment of Spinal Cord Injury and Neurodegenerative Diseases

ISSN: 1875-533X (Online)
ISSN: 0929-8673 (Print)

Volume 22, 38 Issues, 2015

Download PDF Flyer

Current Medicinal Chemistry

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 9th of 58 in Chemistry & Medicinal
  • 49th of 254 in Pharmacology & Pharmacy
  • 96th of 291 in Biochemistry & Molecular Biology

Submit Abstracts Online Submit Manuscripts Online

Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.715
5 - Year: 4.239

Phosphodiesterase as a New Therapeutic Target for the Treatment of Spinal Cord Injury and Neurodegenerative Diseases

Author(s): Irene Paterniti, Emanuela Esposito and Salvatore Cuzzocrea

Affiliation: Torre Biologica, Policlinico Universitario Via C. Valeria, Gazzi, 98100 Messina Italy.


Interest in Central Nervous System (CNS) inflammation has rapidly grown over the past decade driven by the increasing evidence indicating that chronic inflammation and neuroinflammation in the brain may play an important role in the progressive neuronal cell death in many chronic CNS diseases, such as Alzheimer and Parkinson’s diseases, traumatic brain injury, spinal cord injury (SCI), as well as pathologies associated with CNS infections. In peripheral tissues, generally inflammation has a protective role limiting the survival and proliferation of invading pathogens, promoting tissue repair and recovery. This innate response normally resolves over a few weeks, accompanyied by tissue repair aided by macrophages recruited to the site. However, when the inflammatory response does not undergo resolution, it might turn into chronic inflammation. Any chronic inflammatory process can damage healthy tissue and the brain may be particularly vulnerable, since destroyed neurons can not be replaced. Recently, several reports have suggested that phosphodiesterases (PDEs) are new targets for central nervous system (CNS) diseases. All the PDEs are expressed in the CNS, making this gene family a particularly attractive source of new targets for the treatment of psychiatric and neurodegenerative disorders. Significantly, all neurons express multiple PDEs, which differ in cyclic nucleotide specificity, affinity, regulatory control and subcellular compartmentalization. Therefore, PDEs inhibition represents a mechanism through which it could be possible to precisely modulate neuronal activity. In this article, we review the current state of art of PDEs in the CNS diseases associated with neuroinflammation.

Keywords: Alzheimer’s disease, chronic Inflammation, neuroinflammation, Parkinson’s disease, PDE inhibitors, spinal cord injury.

Purchase Online Order Reprints Order Eprints Rights and Permissions


Article Details

Volume: 21
Issue Number: 24
First Page: 2830
Last Page: 2838
Page Count: 9
DOI: 10.2174/0929867321666140217102428

Related Journals

Webmaster Contact: Copyright © 2015 Bentham Science